Melero, Ignacio
Gaudernack, Gustav
Gerritsen, Winald
Huber, Christoph
Parmiani, Giorgio
Scholl, Suzy
Thatcher, Nicholas
Wagstaff, John
Zielinski, Christoph
Faulkner, Ian
Mellstedt, HÃ¥kan
Article History
First Online: 8 July 2014
Competing interests
: I.F. has received a research grant from Merck KGaA. Views and opinions described do not necessarily reflect those of Merck KGaA. I.M. has provided consultancy to and received honoraria and research funding from Bristol-Myers Squibb. G.G. is employed by Ultimovacs AS and has stocks in Ultimovacs AS and Targovax AS and he has provided consultancy to and received honoraria from KAEL-GemVax and Lytix AS. C.H. is an employee and has stocks in BioNTech and GANYMED Pharmaceuticals, has provided consultancy to Apceth, Bayer, Baxter, BioNTech, GANYMED, immatics, Merck KGaA, SuppreMol and TRON, and received honoraria from the CCR (UK), Karolinska University, Stockholm (Sweden), Kurume Cluster (Japan), and Swiss National Science Foundation. G.P. has provided consultancy to CureVac and received honoraria from Recombio. S.S. and N.T. have provided consultancy and received honoraria from Merck KGaA and KAELGemVax, and has stocks in Kancera AB. H.M. has received honoraria and research funding from Merck KGaA. W.G., J.W. and C.Z. declare no competing interests.